Sydbank share buyback programme: transactions in week 18
May 06, 2024 06:15 ET
|
Sydbank A/S
Company Announcement No 16/2024Peberlyk 46200 AabenraaDenmarkTel +45 74 37 37 37Fax +45 74 37 35 36Sydbank A/SCVR No DK 12626509, Aabenraasydbank.dk6 May 2024 Dear Sirs Sydbank share...
H World Group Limited Schedules First Quarter of 2024 Earnings Release on May 17, 2024
May 06, 2024 06:15 ET
|
H World Group Limited
SINGAPORE and SHANGHAI, China, May 06, 2024 (GLOBE NEWSWIRE) -- H World Group Limited (NASDAQ: HTHT and HKEX: 1179) (“H World”, “we” or “our”) a key player in the global hotel industry, today...
Verkkokauppa.com Oyj - Managers' Transactions – Seppälä
May 06, 2024 06:15 ET
|
Verkkokauppa.com Oyj
Verkkokauppa.com Oyj - Managers' Transactions – Seppälä Verkkokauppa.com Oyj MANAGERS’ TRANSACTIONS 6 May 2024 at 1:15 p.m. EEST Verkkokauppa.com Oyj has received a notification from...
ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
May 06, 2024 06:10 ET
|
ADC Therapeutics SA
ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $17.8 million in 1Q 2024; total operating expenses decreased 25% (adjusted total operating expenses decreased 16%)1 compared to 1Q 2023 ...
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
May 06, 2024 06:05 ET
|
MannKind
MANNKIND RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR CLOFAZIMINE INHALATION SUSPENSION FOR THE TREATMENT OF SERIOUS LUNG DISEASE
CREDIT AGRICOLE SA : DECLARATION DES DROITS DE VOTE AVRIL 2024
May 06, 2024 06:02 ET
|
CREDIT AGRICOLE SA
Raison sociale de l’émetteur : Crédit Agricole S.A. – SA au capital de 9 077 707 050 eurosImmatriculée sous le n° 784 608 416 R.C.S. NANTERRESiège social : MONTROUGE (92120) 12, place des Etats-Unis ...
Integra LifeSciences Reports First Quarter 2024 Financial Results
May 06, 2024 06:00 ET
|
Integra LifeSciences Holdings Corporation
PRINCETON, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the...
ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma
May 06, 2024 06:00 ET
|
ADC Therapeutics SA
Initial data from 15 patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL) show 13 patients achieved a complete response and one patient achieved a partial response with ZYNLONTA® All...
Brains Bioceutical Announces the Addition of Industry Veteran John Boshart to its Animal Health Division
May 06, 2024 06:00 ET
|
Brains Bioceutical Corp
VANCOUVER, British Columbia, May 06, 2024 (GLOBE NEWSWIRE) -- Today marks a pivotal development for Brains Bioceutical Corp ("Brains Bio"), as it significantly strengthens its Veterinary Health...
AsclepiX Therapeutics Completes Enrollment in DISCOVER Trial for Neovascular Age-Related Macular Degeneration (nAMD)
May 06, 2024 06:00 ET
|
Asclepix
The DISCOVER Phase 1/2a trial is an open-label, single ascending dose, 9-month study that will evaluate the safety and bioactivity of AXT107 (gersizangitide) injected suprachoroidally in patients with...